Key result
A novel parvovirus-like virus, NIH-CQV, was detected by quantitative PCR in 70% of patients with non-A-E hepatitis compared to 0% of healthy controls.
Case-Control (n=137)
Absolute Event Rate: 70% vs 0%
A novel parvovirus-like hybrid DNA virus (NIH-CQV) is highly prevalent in Chinese patients with seronegative hepatitis compared to healthy controls.
NIH-CQV association with non-A-E hepatitis merits etiologic investigation; Level 4 case-control data leave open causality.
Seronegative hepatitis--non-A, non-B, non-C, non-D, non-E hepatitis--is poorly characterized but strongly associated with serious complications. We collected 92 sera specimens from patients with non-A-E hepatitis in Chongqing, China between 1999 and 2007. Ten sera pools were screened by Solexa deep sequencing. We discovered a 3,780-bp contig present in all 10 pools that yielded BLASTx E scores of 7e-05-0.008 against parvoviruses. The complete sequence of the in silico-assembled 3,780-bp contig was confirmed by gene amplification of overlapping regions over almost the entire genome, and the virus was provisionally designated NIH-CQV. Further analysis revealed that the contig was composed of two major ORFs. By protein BLAST, ORF1 and ORF2 were most homologous to the replication-associated protein of bat circovirus and the capsid protein of porcine parvovirus, respectively. Phylogenetic analysis indicated that NIH-CQV is located at the interface of Parvoviridae and Circoviridae. Prevalence of NIH-CQV in patients was determined by quantitative PCR. Sixty-three of 90 patient samples (70%) were positive, but all those from 45 healthy controls were negative. Average virus titer in the patient specimens was 1.05 e4 copies/µL. Specific antibodies against NIH-CQV were sought by immunoblotting. Eighty-four percent of patients were positive for IgG, and 31% were positive for IgM; in contrast, 78% of healthy controls were positive for IgG, but all were negative for IgM. Although more work is needed to determine the etiologic role of NIH-CQV in human disease, our data indicate that a parvovirus-like virus is highly prevalent in a cohort of patients with non-A-E hepatitis.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2013) conducted a case-control in Seronegative hepatitis (non-A-E hepatitis) (n=137). NIH-CQV infection vs. Healthy controls was evaluated on Prevalence of NIH-CQV by quantitative PCR. A novel parvovirus-like virus, NIH-CQV, was detected by quantitative PCR in 70% of patients with non-A-E hepatitis compared to 0% of healthy controls.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: